LMR Partners’s Cardiff Oncology CRDF Stock Holding History

LMR Partners’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-155,000	Closed	-$488K	–	1480
2025 Q2	$488K	Buy	155,000 +30,000	+24%	+$91.5K	﹤0.01%	951
2025 Q1	$393K	Buy	+125,000	New	+$494K	﹤0.01%	956

Other funds holding CRDF

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FLPIM

F.L. Putnam Investment Management Lynnfield, Massachusetts $6.71B AUM 23.99% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

LMR Partners's CRDF Position: Q2 2024 in Review

LMR Partners sold out of Cardiff Oncology (CRDF) in Q2 2024, closing a stake of 13,101 shares — an estimated $70K sold.

LMR Partners first reported a position in CRDF in Q2 2017 and held it in 5 quarters. The position peaked at $216K in Q1 2021. 90 funds tracked by Wall St. Rank hold CRDF as of Q2 2024.

LMR Partners reported no remaining Cardiff Oncology position as of Q2 2024 after selling out during the quarter.
LMR Partners sold 13,101 Cardiff Oncology shares in Q2 2024, an estimated $70K.
LMR Partners first reported a position in Cardiff Oncology in Q2 2017 and held it in 5 quarters.
LMR Partners's Cardiff Oncology position peaked at $216K in Q1 2021.
90 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2024.

Based on LMR Partners's 13F filing for Q2 2024, filed 14 Aug 2024.